HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report published on Thursday morning, Benzinga reports. The brokerage currently has a $7.00 target price on the stock.
Immix Biopharma Trading Up 21.6 %
IMMX opened at $1.63 on Thursday. The stock’s 50 day simple moving average is $1.93 and its 200-day simple moving average is $2.19. The stock has a market cap of $43.05 million, a PE ratio of -1.75 and a beta of 0.12. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. Equities analysts forecast that Immix Biopharma will post -0.64 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Immix Biopharma
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
See Also
- Five stocks we like better than Immix Biopharma
- 3 Warren Buffett Stocks to Buy Now
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Dividend Payout Ratio Calculator
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.